Galderma has provided a progress update on its Biologics License Application (BLA) for RelabotulinumtoxinA, a botulinum toxin candidate under FDA review. The update confirms ongoing regulatory engagement but does not disclose an expected decision date.
Regulatory
Galderma Provides Update on RelabotulinumtoxinA BLA Review — Third Botulinum Toxin Competitor Advances
Galderma's neuromodulator candidate moves through FDA Biologics License Application review.
1-YEAR MOVE
ABBV
▲11.6%
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
| EOLS | Evolus | −15.6% |
A third botulinum toxin competitor advances through FDA review, fragmenting the market and pressuring toxin rebate structures.
RelabotulinumtoxinA would join Revance's DaxibotulinumtoxinA (Daxxify) as the second non-AbbVie neuromodulator approved in the U.S., fragmenting the botulinum toxin market beyond Botox and Jeuveau. For practices, a third entrant reshapes toxin economics: it pressures rebate structures across Allergan Aesthetics' Allē loyalty program and Evolus's Evolus Rewards, potentially widening access to alternative toxins and forcing manufacturers to compete on per-unit pricing and loyalty terms. Galderma's existing dermatology footprint (Restylane, Sculptra) positions it to bundle RelabotulinumtoxinA into practice agreements.
Source: original report ↗
Frequently asked questions
What is RelabotulinumtoxinA and when will it be approved?
RelabotulinumtoxinA is Galderma's botulinum toxin candidate currently under FDA Biologics License Application review. Galderma has not disclosed an expected decision date, but the company continues active regulatory engagement with the FDA.
How will a third botulinum toxin competitor affect med spa pricing?
A third toxin entrant like RelabotulinumtoxinA will pressure rebate structures in loyalty programs like Allergan Aesthetics' Allē and Evolus Rewards, forcing manufacturers to compete on per-unit pricing and loyalty terms. This competition typically widens access to alternative toxins and can reduce practice costs.
What botulinum toxins are currently approved in the US besides Botox?
Botox and Jeuveau dominate the market, with Revance's DaxibotulinumtoxinA (Daxxify) approved as the first non-AbbVie neuromodulator. RelabotulinumtoxinA would become the second non-AbbVie option if approved.
Will Galderma bundle RelabotulinumtoxinA with Restylane and Sculptra?
Galderma's existing dermatology footprint with Restylane and Sculptra positions it to bundle RelabotulinumtoxinA into practice agreements, potentially offering volume discounts or tiered pricing for multi-product commitments.
How does RelabotulinumtoxinA differ from Daxxify?
The article does not provide clinical or formulation differences between RelabotulinumtoxinA and Daxxify; both are non-AbbVie botulinum toxin candidates competing to fragment the market beyond Botox and Jeuveau.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.